Alexander Todd
AstraZeneca (Singapore) · 7 works · 3,286 citations · h-index 5
Top works
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
- Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer
- Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
- Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
- Abstract LB294: Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib
- Evaluation of MET Detection Methods and Cutoffs in EGFR -Mutated Non–Small Cell Lung Cancer following Disease Progression on Osimertinib in the Phase II SAVANNAH Study